Companies › Clarion Cells
1 active drug program in 1 registered trial: 1 Phase 1; Neurology; next expected readout Aug 2029.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NR1 Human embryonic stem cell (hESC) derived neural stem cells for tissue repair and regenerat | – | Phase 1 | Ischemic Stroke | Aug 2029 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04631406 | NR1 | Phase 1 | Ischemic Stroke | Neurology | Aug 2029 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.